Physician profile
Neha Kumar
NPI 1467912428
$5,202.00
in general payments reported to CMS, 2019-2025
25 companies · $4,684 in 2025
The $4,684 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $518 · 2025: $4,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,102.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.57 | 2024-2025 | |
| Abbott Laboratories | $779.24 | 2025 | Eterna |
| Pfizer INC. | $332.15 | 2024-2025 | |
| Tg Therapeutics, INC. | $309.66 | 2025 | |
| Ucb, INC. | $284.70 | 2024-2025 | Nayzilam, Briviact, Rystiggo |
| Lilly USA, LLC | $227.85 | 2024-2025 | Kisunla |
| Emd Serono, INC. | $222.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $220.62 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $220.57 | 2025 | Bafiertam, Tascenso Odt |
| Lundbeck LLC | $204.25 | 2025 | Vyepti |
| Neurocrine Biosciences, INC. | $186.22 | 2024-2025 | Ingrezza |
| Sk Life Science, INC. | $149.89 | 2025 | |
| Argenx US, INC. | $119.82 | 2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $99.99 | 2025 | |
| Neurelis, INC. | $88.98 | 2024-2025 | Valtoco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $84.34 | 2025 | |
| Celgene Corporation | $84.05 | 2025 | Zeposia |
| Axsome Therapeutics, INC. | $82.32 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $66.13 | 2025 | Crexont |
| Amgen INC. | $55.69 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $51.95 | 2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $50.76 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $50.42 | 2025 | Austedo Xr |
| C2n Diagnostics, LLC | $24.13 | 2025 | Precivityad2 |
| Genentech USA, INC. | $23.73 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.